ReAlta Life Sciences

About ReAlta Life Sciences

ReAlta Life Sciences is a clinical-stage biopharmaceutical company focused on rare inflammatory diseases. The company develops a novel dual-targeting therapeutic approach that modulates innate inflammation by targeting both the complement system and neutrophil-driven pathways, with its lead program pegtarazimod (RLS-0071) aimed at altering disease progression. Its research emphasizes immune balance to treat conditions such as hypoxic ischemic encephalopathy, graft-versus-host disease, and other autoimmune- and inflammation-related disorders. Headquartered in Norfolk, Virginia with operations and presence in Puerto Rico, the company advances its pipeline through research and development for acute inflammatory conditions.